Dr Vickie Driver appointed Executive Vice President, Global Head of Tissue Repair & Regenerative Medicine

Nov 27, 2019

Thirty Group announces the appointment of Dr. Vickie Driver as Executive Vice President, Global Head of Tissue Repair & Regenerative Medicine. Dr. Driver was Director, Translational Medicine at Novartis Institute for BioMedical Research and is a former Professor of Surgery in the Department of Orthopedics at Brown University (Clinical) and Associate Professor of Surgery at Boston University. She has recently completed her tenure as president for the Advancement of Wound Care Association (AAWC) and has served for 9 years on the Board of Directors. She also proudly serves as a member of the Wound Healing Society (WHS) Board of Directors and as member Board of Directors for the Critical Limb Ischemia (CLI) Global Society and chairs the wound healing committee. As principle investigator, she has served on and initiated more than 70 important multi-center randomized clinical trials, as well as developed and supervised multiple research fellowship training programs.  She has co-authored well over 100 publications and abstracts.

Vickie is a Fellow at the American College of Foot and Ankle Surgeons, licensed in MA and RI and is board certified in foot surgery by the American Board of Podiatric Surgery. She has been recently selected as Fellow, Royal College of Physicians and Surgeons-Glasgow, PM. Her career has a special emphasis on tissue repair and limb preservation, and she is an outspoken ambassador for progressive change in this field that will directly benefit improving care to patients.

Commenting on the appointment Syd Hanna, Board Director said: “We are delighted to welcome Dr Driver to our Executive leadership team to lead our build-out in regenerative medicine, a very important part of our business. Dr. Driver has a distinguished career in the field of podiatric medicine and surgery, with a special emphasis on limb preservation and wound healing. She is nationally and internationally regarded as a premiere clinician, surgeon, researcher and educator”.

30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.

30 TECHNOLOGY Therapeutic Nitric Oxide